Furthermore, regarding anti-inflammatory activity, CIGB-258 showed similar features to an IL-6 inhibitor (Tocilizumab) than a TNF-α inhibitor (Infliximab) to protect zebrafish and embryos from acute death by CML treatment. The gene discussed is TNF; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.